Foo Caroline S, Abdelnabi Rana, Vangeel Laura, De Jonghe Steven, Jochmans Dirk, Weynand Birgit, Neyts Johan
KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Global Virus Network, GVN, 725 West Lombard St, Room S413, Baltimore, MD 21201, USA.
Microorganisms. 2022 Mar 16;10(3):633. doi: 10.3390/microorganisms10030633.
Ivermectin, an FDA-approved antiparasitic drug, has been reported to have in vitro activity against SARS-CoV-2. Increased off-label use of ivermectin for COVID-19 has been reported. We here assessed the effect of ivermectin in Syrian hamsters infected with the SARS-CoV-2 Beta (B.1.351) variant. Infected animals received a clinically relevant dose of ivermectin (0.4 mg/kg subcutaneously dosed) once daily for four consecutive days after which the effect was quantified. Ivermectin monotherapy did not reduce lung viral load and even significantly worsened SARS-CoV-2-induced lung pathology. Additionally, it did not potentiate the activity of molnupiravir (Lagevrio) when combined with this drug. This study contributes to the growing body of evidence that ivermectin does not result in a beneficial effect in the treatment of COVID-19. These findings are important given the increasing, dangerous off-label use of ivermectin for the treatment of COVID-19.
伊维菌素是一种经美国食品药品监督管理局（FDA）批准的抗寄生虫药物，据报道其在体外对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）具有活性。据报道，伊维菌素在治疗新冠肺炎时的非标签使用有所增加。我们在此评估了伊维菌素对感染SARS-CoV-2贝塔（B.1.351）变体的叙利亚仓鼠的影响。感染动物在连续四天每天接受一次临床相关剂量的伊维菌素（皮下注射剂量为0.4毫克/千克）后，对其效果进行量化。伊维菌素单一疗法并未降低肺部病毒载量，甚至显著加重了SARS-CoV-2诱导的肺部病理状况。此外，当与莫努匹拉韦（拉格维里奥）联合使用时，伊维菌素也未增强其活性。这项研究为越来越多的证据提供了补充，即伊维菌素在治疗新冠肺炎时不会产生有益效果。鉴于伊维菌素在治疗新冠肺炎时越来越多的危险的非标签使用情况，这些发现具有重要意义。
